what i found interesting in the presentation was that neuren wants to keep commercial rights for NA 2591 and licence out row 2591 rights first (opposite to trof). possibly, they could package trof and 2591 ROW rights together as one deal that might attract bigger pharma.
if this is lucrative enough, it (with the Acadia money) could finance a couple of phase 3 trials.
what i found interesting in the presentation was that neuren...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.25 |
Change
0.430(2.17%) |
Mkt cap ! $2.585B | |||
| Open | High | Low | Value | Volume |
| $19.89 | $20.39 | $19.77 | $5.715M | 283.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 355 | $20.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.29 | 302 | 1 |
View Market Depth
| Last trade - 16.10pm 07/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.22 |
Change
0.430 ( 2.40 %) |
||||
| Open | High | Low | Volume | ||
| $19.86 | $20.40 | $19.77 | 85257 | ||
| Last updated 15.59pm 07/05/2024 ? | |||||
| NEU (ASX) Chart |